Outlook on the Genomics Global Market to 2027 – Adoption of Genomics in Specialized/Personalized Medicine – Benzinga

DUBLIN, May 24, 2022 /PRNewswire/ --The "Global Genomics Market By Product & Service, By Application, By End User, By Technology, By Regional Outlook, Industry Analysis Report and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The Global Genomics Market size is expected to reach $68.9 billion by 2027, rising at a market growth of 17.5% CAGR during the forecast period.

A genome is an organism's genetic material. It includes genes, noncoding DNA, mitochondrial DNA, and chloroplast DNA, among other things. Genomic refers to the science and study of genomes. Because of its applicability in numerous fields of study, such as intragenomic phenomena such as epistasis, pleiotropy, heterosis, and other interactions between loci and alleles inside the genome, genomics is gaining massive traction in the market.

According to the National Cancer Institute, the number of new cancer cases is expected to rise to 29.5 million by 2040, and the number of cancer-related fatalities will rise to 16.4 million per year. The requirement for vast amounts of DNA data to be stored, sequenced, and analyzed has opened the way for novel goods and software. In recent years, the aforementioned factors have played a crucial role in propelling the industry.

The increasing government funding for genomics projects, the rising incidence of cancer and increasing applications of NGS in cancer research, the entry of new players and start-ups into the genomics market, and the growing application areas of genomics are the major factors driving the market's growth.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic has increased the burden on healthcare sector. The imposition of restrictions like complete or partial lockdown, temporary ban on manufacturing units and ban on imports & exports has negatively impacted various sectors of the business domain. The Covid-19 pandemic has drastically transformed the healthcare business as a whole, with the pandemic's effects felt in all areas of healthcare.

Both the government and commercial pharmaceutical and biotechnological businesses have intensified their research efforts and investments in order to create an effective or new COVID-19 treatment. The coronavirus genome sequence can be used to trace the spread of infection and its influence on the human genome. This information can subsequently be used to create an efficient infection treatment.

Market Growth Factors:

Innovative Product Launch and Technological Advancements

Several new products and services have emerged as a result of the trend toward individualized medications and lower sequencing costs due to the launch of NGS technology. With new competitors entering the market, the market is becoming increasingly competitive, and enterprises are responding by developing innovative products and services to strengthen their positions.

Adoption of genomics in specialized/personalized medicine

Personalized medicine research is becoming more popular among pharmaceutical corporations. Personalized medicine allows doctors to pinpoint a patient's specific needs and then prescribe medications and treatments to meet those needs. This method ensures improved treatment outcomes. In addition, advances in the field of gene therapy are projected to enable doctors to treat a problem by inserting a gene into a patient's cell, potentially replacing existing medications and operations.

Marketing Restraining Factor:

Growing concerns about Privacy

Genome sequencing not only offers information about the procedure's subject but also about those who are closely related to it. As a result, genomic data may have an impact on connections with other family members. Other family members may not want to know such details, or the client may choose to keep some information private. However, such knowledge may have significant ramifications for family members' well-being, and the client may be left with the difficult problem of determining what information to reveal and what information to keep hidden.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview 2.1 Introduction 2.1.1 Overview 2.1.1.1 Market Composition and Scenario 2.2 Key Factors Impacting the Market 2.2.1 Market Drivers 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global 3.1 KBV Cardinal Matrix 3.2 Recent Industry Wide Strategic Developments 3.2.1 Partnerships, Collaborations and Agreements 3.2.2 Product Launches and Product Expansions 3.2.3 Acquisition and Mergers 3.3 Top Winning Strategies 3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021) 3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2017, Jan - 2021, Dec) Leading Players

Chapter 4. Global Genomics Market by Product & Service 4.1 Global Consumables Market by Region 4.2 Global Systems & Software Market by Region 4.3 Global Services Market by Region

Chapter 5. Global Genomics Market by Application 5.1 Global Drug Discovery & Development Market by Region 5.2 Global Diagnostics Market by Region 5.3 Global Agriculture & Animal Research Market by Region 5.4 Global Others Market by Region

Chapter 6. Global Genomics Market by End User 6.1 Global Hospitals & Clinics Market by Region 6.2 Global Research Centers and Academic & Government Institutes Market by Region 6.3 Global Pharmaceutical & Biotechnology Companies Market by Region 6.4 Global Others Market by Region

Chapter 7. Global Genomics Market by Technology 7.1 Global Sequencing Market by Region 7.2 Global PCR Market by Region 7.3 Global Nucleic Acid Extraction & Purification Market by Region 7.4 Global Microarray Market by Region 7.5 Global Others Market by Region

Chapter 8. Global Genomics Market by Region

Chapter 9. Company Profiles 9.1 Creative Biogene 9.1.1 Company Overview 9.2 Thermo Fisher Scientific, Inc. 9.2.1 Company Overview 9.2.2 Financial Analysis 9.2.3 Segmental and Regional Analysis 9.2.4 Research & Development Expense 9.2.5 Recent strategies and developments 9.2.5.1 Partnerships, Collaborations, and Agreements 9.2.6 SWOT Analysis 9.3 Illumina, Inc. 9.3.1 Company Overview 9.3.2 Financial Analysis 9.3.3 Regional Analysis 9.3.4 Research & Development Expense 9.3.5 Recent strategies and developments 9.3.5.1 Partnerships, Collaborations, and Agreements 9.3.5.2 Acquisition and Mergers: 9.4 Bio-Rad laboratories, Inc. 9.4.1 Company Overview 9.4.2 Financial Analysis 9.4.3 Segmental and Regional Analysis 9.4.4 Research & Development Expenses 9.4.5 Recent strategies and developments 9.4.5.1 Partnerships, Collaborations, and Agreements 9.4.5.2 Product Launches and Product Expansions 9.4.5.3 Acquisition and Mergers: 9.5 Danaher Corporation 9.5.1 Company Overview 9.5.2 Financial Analysis 9.5.3 Segmental and Regional Analysis 9.5.4 Research & Development Expense 9.5.5 Recent strategies and developments 9.5.5.1 Acquisition and Mergers: 9.6 Agilent Technologies, Inc. 9.6.1 Company Overview 9.6.2 Financial Analysis 9.6.3 Segmental and Regional Analysis 9.6.4 Research & Development Expense 9.6.5 Recent strategies and developments 9.6.5.1 Partnerships, Collaborations, and Agreements 9.6.5.2 Product Launches and Product Expansions 9.6.5.3 Acquisition and Mergers: 9.7 F. Hoffmann-La Roche Ltd. 9.7.1 Company Overview 9.7.2 Financial Analysis 9.7.3 Segmental and Regional Analysis 9.7.4 Research & Development Expense 9.7.5 Recent strategies and developments 9.7.5.1 Partnerships, Collaborations, and Agreements 9.7.5.2 Product Launches and Product Expansions 9.7.5.3 Acquisition and Mergers: 9.8 Eurofins Scientific Group 9.8.1 Company Overview 9.8.2 Financial Analysis 9.8.3 Regional Analysis 9.8.4 Recent strategies and developments 9.8.4.1 Acquisition and Mergers: 9.9 Qiagen N.V. 9.9.1 Company Overview 9.9.2 Financial Analysis 9.9.3 Regional Analysis 9.9.4 Research & Development Expense 9.9.5 Recent strategies and developments 9.9.5.1 Partnerships, Collaborations, and Agreements 9.9.5.2 Product Launches and Product Expansions 9.9.5.3 Acquisition and Mergers: 9.10. New England BioLabs, Inc. 9.10.1 Company Overview 9.10.2 Recent strategies and developments 9.10.2.1 Product Launches and Product Expansions

For more information about this report visit https://www.researchandmarkets.com/r/8ixx3z

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/outlook-on-the-genomics-global-market-to-2027---adoption-of-genomics-in-specializedpersonalized-medicine-is-driving-growth-301554171.html

SOURCE Research and Markets

The rest is here:
Outlook on the Genomics Global Market to 2027 - Adoption of Genomics in Specialized/Personalized Medicine - Benzinga

In first, Verve gets clearance to test base editing inside the body – BioPharma Dive

Dive Brief:

New Zealands decision to clear human testing represents a notable achievement for Verve and another important milestone for the type of gene editing technology the company is developing. Known as base editing, it's a potentially more precise way to modify genes, enabling scientists and drugmakers to change single DNA "letters."

Base editing builds on the progress made with CRISPR-based editing and has rapidly moved from laboratories into clinics. Beam Therapeutics, which licenses technology to Verve, won U.S. approval in November to begin a clinical trial of a base editing therapy for sickle cell disease. Unlike Beam's treatment, Verve's is designed to do its work inside the body, rather than on cells taken out of the body and modified in a lab. It's now the third inside-the-body gene editing treatment to enter human trials, following experimental drugs from Intellia Therapeutics and Editas Medicine.

While Tuesday's news is a milestone, Verve has a long way to go. Though the company is initially targeting a rare condition, it ultimately seeks to conquer one of the most prevalent diseases in the world. Even if the technology succeeds, Verve will have to persuade doctors and patients to adopt a potentially expensive genetic therapy when other, comparatively cheaper drugs exist to lower cholesterol and prevent some of the worst effects of heart disease.

For example, drugmakers in recent years have introduced several injectable medicines that specifically target PCSK9. While they had dramatic effects on cholesterol levels, insurers balked at the initial prices. The drugs are mostly used for patients at the most risk of a heart attack.

Verve CEO Sekar Kathiresan argues that his company's approach, if proven in clinical trials, offers an approach that will not only save lives, but also money for the healthcare system. He envisions a therapy akin to a vaccine for heart attacks thats not dependent on taking pills or receiving injections for life.

Verve has been publicly traded for less than a year, having raised $267 million in an initial public offering in June. While its IPO was one of the most successful in the biotech industry in 2021, the companys share price has tumbled along with its biotech peers in recent months. Once soaring above $70, Verve shares now trade around $13 apiece.

Link:
In first, Verve gets clearance to test base editing inside the body - BioPharma Dive

Canavan Disease Treatment Market to Witness Robust Expansion throughout the Forecast Period to 2028 – Digital Journal

Canavan Disease Treatment market document takes into consideration the market type, size of the organization, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa to analyse the data. The report also describes all the major topics of the market research analysis that includes market definition, market segmentation, competitive analysis, major developments in the market, and excellent research methodology. Clients can reveal the best opportunities to be successful in the market with an excellent practice models and method of research used while creating Canavan Disease Treatment market report.

Download Exclusive Sample (350 Pages PDF) Report:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-canavan-disease-treatment-market

Key Segmentation:

By Treatment (Gene Therapy, Drug Therapy, Others)

By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

List of the Leading Companies Profiled in the Canavan Disease Treatment Market are:

Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, F. Hoffmann-La Roche Ltd., and Amgen, Inc

Brief Overview on Market:

The report covers profiling of key market players with overall business operations, news coverage, product portfolio, geographic presence, and financial status. Value chain analysis is provided, which is combined with the competitive landscape of key players of the market. Market size and forecast of the Canavan Disease Treatment market for the period has been given. Global presence of the market, market dynamics, and evaluation by upstream and downstream of raw materials have been discussed.

The Global Canavan Disease Treatment Marketresearch to provide market definition, the report neatly researches market driving factors. The report has been created after detailed and exhaustive studies several factors into consideration like monetary, ecological, social, mechanical, and political status of a particular demography. Moreover, it offers noteworthy data along with future forecast and thorough analysis of the market on a global and regional level. Expert solutions combined with potential capabilities make this Canavan Disease Treatment market report outshining.

Key stakeholders in Market including industry players, policymakers, and investors in various countries have been continuously realigning their strategies and approaches to implement them in order to tap into new opportunities. Price point comparison by region with the global average price is also considered in the study.

Canavan Disease Treatment Market Segments by Geography

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

The key countries in each region are taken into consideration as well, such as United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Highlights of the Report

In-depth analysis of various insights, namely, Canavan Disease Treatment Market trends, growth drivers, opportunities, and other related challenges.

Comprehensive details of key market players, their core competencies, and market shares.

The potency of suppliers and buyers to make better business decisions.

Lists out the market size in terms of volume.

Key Highlights from the Canavan Disease Treatment Market Outlook Report:

Elaborated scenario of the parent marketTransformations in the Canavan Disease Treatment market dynamics, Canavan Disease Treatment market trends, growth drivers, opportunities, and other related challenges.Detailed segmentation of the target marketHistorical, current and forecast of Canavan Disease Treatment market size based on value and volumeLatest industry developments and Comprehensive details of key market players, their core competencies, and market shares.Competitive analysis of Canavan Disease Treatment MarketStrategies adopted by the Canavan Disease Treatment industry key players and product developments madePotential and niche segments, along with their regional analysis & surveyUnbiased analysis on market growth and Lists out the market size in terms of volume of Canavan Disease Treatment marketUp-to-date and must-have intelligence for the market players to enhance and sustain their competitiveness

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-canavan-disease-treatment-market

Comprehensive Market Coverage as part of its offering, this report includes:

COVID-19 Testing Markets, Current, Future and Projected.

Impact onCanavan Disease Treatment Market, 2021 and 2022

350+ Page Report Based on Vendor Reporting, Interviews, Vendor Activities

Detailed Market Chapters with 2022 Market Estimates

Market Segment Projections to 2028

Regional Breakouts Including Country Canavan Disease Treatment Markets

Coverage of Growth Markets

Superior Company Profiles of Top Tier Companies and Hundreds of Smaller Concerns

Industry-Standard Business Planning Tools

Coverage of Trends and Market Estimates for Essential Canavan Disease Treatment Segments

Buy Full Report:https://www.databridgemarketresearch.com/reports/global-canavan-disease-treatment-market

The data provided in the Canavan Disease Treatment Demand report offers comprehensive analysis of important industry trends. Industry players can use this data to strategize their potential business moves and gain remarkable revenues in the upcoming period.

The report covers the price trend analysis and value chain analysis along with analysis of diverse offering by Key vendors. The main motive of this Survey report is to assist enterprises to make data-driven decisions and strategize their business moves.

Browse Similar Reports:

https://www.marketwatch.com/press-release/rotavirus-prophylaxis-market-scope-and-overview-growth-study-future-trends-and-top-players-by-forecast-to-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/specimen-containers-market-2022-size-future-trends-global-regions-impact-of-covid-19-gross-margin-regional-demand-and-forecast-to-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/sialorrhea-market-share-industry-growth-trend-drivers-challenges-key-companies-by-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/europe-tumor-ablation-market-to-witness-robust-expansion-throughout-the-forecast-period-to-2029-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/life-science-software-market-reportknow-the-latest-innovations-and-trends-to-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/magnetic-resonance-imaging-mri-systems-market-size-share-growth-trends-and-forecast-20222028-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/bone-spur-market-forecast-business-opportunities-size-share-scope-forecast-to-2028-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/cyclin-dependent-kinase-inhibitor-market-size-2028by-application-type-manufacturers-across-north-america-europe-apac-south-america-mea-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/celiac-drugs-market-size-share-and-forecast-2028-segmentation-key-insights-and-company-profiles-takeda-pharmaceutical-company-limited-amgen-inc-cour-pharmaceuticals-development-company-inc-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/smart-health-watches-market-production-size-key-trends-challenges-top-key-players-and-forecast-to-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/muckle-wells-syndrome-market-growth-share-trend-business-opportunities-manufacturers-and-research-methodology-by-2027-2022-05-09?mod=search_headline

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Go here to see the original:
Canavan Disease Treatment Market to Witness Robust Expansion throughout the Forecast Period to 2028 - Digital Journal

Precision Cancer Therapies Market to Witness Robust Expansion by 2029 | Abbott Laboratories, Bayer HealthCare SMU Daily Mustang – SMU Daily Mustang

California (United States) Precision Cancer Therapies Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share, and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:

Some of the Top companies Influencing this Market include:

Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global

Global Precision Cancer Therapies Market Segmentation:

Market Segmentation: By Type

Hormone Therapy, Immunotherapies, Targeted Therapy, Monoclonal Antibody Therapy, Gene Therapy

Market Segmentation: By Application

Hospitals, Diagnostic Centers, Oncology Clinics, Research Institutes

The report provides insights on the following pointers:

Market Penetration: Comprehensive data on the product portfolios of the top players in the Precision Cancer Therapies market.

Product Development/Innovation: Detailed information about upcoming technologies, R&D activities, and market product debuts.

Competitive Assessment: An in-depth analysis of the markets top companies market strategies, as well as their geographic and business segments.

Market Development: Information on developing markets in its entirety. This study examines the market in several geographies for various segments.

Market Diversification: Extensive data on new goods, untapped geographies, recent advancements, and investment opportunities in the Precision Cancer Therapies market.

Get Up to 30% Discount on the first purchase of this report @:

Global Precision Cancer Therapies market Report Scope:

The cost analysis of the Global Precision Cancer Therapies Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Key questions answered in this report:

Table of Contents

Global Precision Cancer Therapies Market Research Report 2022 2029

Chapter 1 Precision Cancer Therapies Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Precision Cancer Therapies Market Forecast

Buy Exclusive Report:

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

+1 775 237 4147

See the original post:
Precision Cancer Therapies Market to Witness Robust Expansion by 2029 | Abbott Laboratories, Bayer HealthCare SMU Daily Mustang - SMU Daily Mustang

Phenylketonuria (PKU) Treatment Market Research Study, Future Prospects and Growth Drivers to 2029 | Top Key Vendors American Gene Tech, Abbott,…

The Global Phenylketonuria (PKU) Treatment Market is expected to gain market growth at a potential rate of 10.95% in the forecast period of 2022 to 2029.

Todays businesses are more inclined towards the market research report because it supports with the improved decision making, more revenue generation, prioritize market goals and achieve profitable business. Analysis and estimations derived through the huge information collected in this market report are extremely essential when it comes to dominating the market or creating a mark in the market as a rising emergent. Global Phenylketonuria (PKU) Treatment Market report is all-inclusive of the data which includes market definition, classifications, applications, engagements, market drivers and market restraints that are derived from SWOT analysis.

The leading Phenylketonuria (PKU) Treatment Market research report provides market definition in the form of market driving factors and market restraints which aids in estimating the requirement of particular product where several aspects have to be considered. Similarly, market segmentation is another significant parameter that categorises the market depending upon application, vertical, deployment model, end-user, and geography etc. To carry out competitive analysis, various strategies of the major players in the market have been taken into account that range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others which lead to an ascend of their footprints in the market. The winning Phenylketonuria (PKU) Treatment Market report includes market shares for global, Europe, North America, Asia Pacific and South America.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-phenylketonuria-pku-treatment-market .

According to market research study, Phenylketonuria is defined as a rare inherited genetic disorder that leads to the increase in levels of phenylalanine in blood. Phenylalanine is an amino acid which is comprised of proteins obtained from food and diet. Phenylalanine hydroxylase enzyme converts phenylalanine in to tyrosine amino acid in human body.

Some of most important key factors driving the growth of the Global Phenylketonuria (PKU) Treatment Market are incidence rate of phenylketonuria, rise in the research in the field of genomics and bioinformatics, rise in the awareness amongst the people, increase in the research in the field of genomics and bioinformatics and increase in the development and commercialization of new drugs.

Global Phenylketonuria (PKU) Treatment Market Segmentation:

Based on the Type, the phenylketonuria (PKU) treatment market is segmented into hyperphenylalaninemia, mild PKU and moderate or variant and classic PKU.

On the basis of Drugs Type, the phenylketonuria (PKU) treatment market is segmented into kuvan, sapropterin, palynziq, pagvaliase and biopten.

On the basis of Therapy Type, the phenylketonuria (PKU) treatment market is segmented into gene therapy and dietary therapy.

On the basis of Route of Administration, the phenylketonuria (PKU) treatment market is segmented into oral, intravenous, subcutaneous and others.

On the basis of End-User, the phenylketonuria (PKU) treatment market is segmented on the basis of end-user into hospitals, homecare, specialty clinics and others.

Regionally, North America dominates the phenylketonuria (PKU) treatment market due to rise in the favorable regulations, rising government initiatives for the treatment of PKU and continuous research and development and commercialization of novel drugs in this region. Europe is the expected region in terms of growth in phenylketonuria (PKU) treatment market due to rise in the awareness amongst the people and increase in the research in the field of genomics and bioinformatics in this region.

Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-phenylketonuria-pku-treatment-market

Top Major Key Players in the Global Phenylketonuria (PKU) Treatment Market:

DAIICHI SANKYO COMPANY LIMITED

Ajinomoto Cambrooke Inc.

American Gene Technologies Inc.

Ultragenyx Pharmaceutical

Danone Nutricia

Reckitt Benckiser Group plc

Abbott

Promin Metabolics

Som innovation biotech SL

Synthetic Biologics Inc.

Nestle

Codexis

BioMarin

Erytech Pharma

Report contents include

1 Analysis of the Phenylketonuria (PKU) Treatment Market includes revenues, future growth, market outlook 2 Historical data and forecast 3 Regional analysis including growth estimates 4 Analyses the end user markets including growth estimates. 5 Profiles on Phenylketonuria (PKU) Treatment including products, sales/revenues, and market position 6 Phenylketonuria (PKU) Treatment Market structure, key drivers and restraints

Get a Complete TOC of Global Phenylketonuria (PKU) Treatment Market Report 2022 @ https://www.databridgemarketresearch.com/toc/?dbmr=global-phenylketonuria-pku-treatment-market .

Global Phenylketonuria (PKU) Treatment Market: Table of Contents

1 Report Overview 2022-2029

2 Global Growth Trends 2022-2029

3 Competition Landscape by Key Players

4 Global Phenylketonuria (PKU) Treatment Market Analysis by Regions

5 Global Phenylketonuria (PKU) Treatment Market Analysis by Type

6 Global Phenylketonuria (PKU) Treatment Market Analysis by Applications

7 Global Phenylketonuria (PKU) Treatment Market Analysis by End-User

8 Key Companies Profiled

9 Global Phenylketonuria (PKU) Treatment Market Manufacturers Cost Analysis

10 Marketing Channel, Distributors, and Customers

11 Market Dynamics

12 Global Phenylketonuria (PKU) Treatment Market Forecasts 2022-2029

13 Research Findings and Conclusion

14 Methodology and Data Source

Get Our More Trending Research Report Here:

1 Asia-Pacific Interventional Neurology Devices Market Trends and Forecast to 2029

2 Europe Beauty Devices Market Industry Trends and Forecast to 2029

3 Global Cistanche Deserticola Market Industry Trends and Forecast to 2029

4 Global Deflectable Catheters Market Industry Trends and Forecast to 2029

5 Global Dental Crown Market Industry Trends and Forecast to 2029

6 Global Epidermal Growth Factor Receptor Inhibitors Market Industry Trends and Forecast to 2029

7 Global Hepatitis C Diagnosis and Treatment Market Industry Trends and Forecast to 2029

8 Global Insulin API Market Industry Trends and Forecast to 2029

9 Global Laparoscopic Electrodes Market Industry Trends and Forecast to 2029

10 Global Sleep Bruxism Market Industry Trends and Forecast to 2029

11 Global Small Molecule Targeted Cancer Therapy Market Industry Trends and Forecast to 2029

12 Global Spasticity Treatment Market Industry Trends and Forecast to 2029

13 Global Surgical Clips Market Industry Trends and Forecast to 2029

14 Global Tachycardia Drugs Market Industry Trends and Forecast to 2029

15 Global Vagus Nerve Stimulation Market Industry Trends and Forecast to 2029

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [emailprotected]

Follow this link:
Phenylketonuria (PKU) Treatment Market Research Study, Future Prospects and Growth Drivers to 2029 | Top Key Vendors American Gene Tech, Abbott,...

Global LKS Treatment Market, By Type, By Treatment, By Diagnosis, By End User, By Region, Competition Forecast and Opportunities, 2017-2027 – Yahoo…

ReportLinker

Global LKS Treatment Market, By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures), By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others), By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast and Opportunities, 2017-2027

New York, April 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global LKS Treatment Market, By Type, By Treatment, By Diagnosis, By End User, By Region, Competition Forecast and Opportunities, 2017-2027" - https://www.reportlinker.com/p06267903/?utm_source=GNW

The global LKS treatment market is projected to register growth at a significate rate during the forecast period.The market growth can be attributed to the rising incidences of genetic disorders like LKS syndrome and the increasing demand for effective treatments for speech impairments.

Landau-Kleffner syndrome (LKS) is a rare neurogenerative disease often affecting children within the age group of 4 to 7 years.The disease caused by gene mutations can affect the speaking and cognitive abilities of the individual.

LKS is more prevalent among males than females.Some of the symptoms of LKS include speech impairment, verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and overt seizures.

Rapidly emerging treatment options for managing and treating the symptoms of LKS are supporting the growth of the global LKS treatment market. Surging demand for effective treatment and the growing number of treatment options are further accelerating the growth of the global LKS treatment market. Rising health awareness among the global population and early diagnosis and effective treatment are also contributing to the growth of the global LKS treatment market. The emergence of diseases similar to LKS is creating a demand for pharmaceutical products and therapeutic treatments, which is anticipated to boost the global LKS treatment market growth. Advancing healthcare infrastructure and the development of better pharmaceutical drugs are also supporting the growth of the global LKS treatment market growth. The global LKS treatment market is segmented on the basis of type, treatment, diagnosis, end user, regional distribution, and competitional landscape.Based on treatment, the market is sub-divided into anticonvulsant drugs, corticosteroids, intravenous immunoglobulins, surgery, speech therapy, and others.

Anticonvulsant drugs are anticipated to register the highest growth in the global LKS treatment market during the forecast period due to rapidly increasing advancements in pharmaceutical products and rising incidences of seizures and convulsions among patients suffering from LKS. Major players operating in the global LKS treatment market are Johnson & Johnson, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Abbott Laboratories, Inc., Cipla, Inc., Glenmark Pharmaceuticals Limited, Mankind Pharma Limited, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, etc.

Years considered for this report:

Historical Years: 2017-2020 Base Year: 2021 Estimated Year: 2022E Forecast Period: 2023F2027F

Objective of the Study:

To analyze the historical growth in the market size of global LKS treatment market from 2017 to 2021. To estimate and forecast the market size of global LKS treatment market from 2022 to 2027 and growth rate until 2027. To classify and forecast global LKS treatment market based on type, treatment, diagnosis, end user, region, and competitive landscape. To identify dominant region or segment in the global LKS treatment market. To identify drivers and challenges for global LKS treatment market. To examine competitive developments such as expansions, new services, mergers & acquisitions, etc., in global LKS treatment market. To identify and analyze the profile of leading players operating in global LKS treatment market. To identify key sustainable strategies adopted by market players in global LKS treatment market.

Report Scope:

In this report, global LKS treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below: LKS Treatment Market, By Type: o Focal Motor Seizures o Tonic Seizures o Atonic Seizures LKS Treatment Market, By Treatment: o Anticonvulsant Drugs o Corticosteroids o Intravenous Immunoglobulins o Surgery o Speech Therapy o Others LKS Treatment Market, By Diagnosis: o Electroencephalogram (EEG) o MRI o Audiometry o Genetic Testing o Others LKS Treatment Market, By End User: o Hospitals & Clinics o Ambulatory Care Centers o Others LKS Treatment Market, By Region: o North America United States Mexico Canada o Europe France Germany United Kingdom Italy Spain o Asia-Pacific China India Japan South Korea Australia o Middle East & Africa South Africa Saudi Arabia UAE o South America Brazil Argentina Colombia

The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of companies across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, TechSci Research was not able to include the companies, which could not be identified due to the limitations of secondary research. The analyst examined the companies and presence of all major players across the globe. The analyst calculated the market size of global LKS treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these treatments for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

LKS treatment service provider companies/partners End-Users Government bodies such as regulating authorities and policy makers Organizations, industry associations, forums and alliances related to global LKS treatment market The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc. besides allowing them in strategizing investments and capitalizing on market opportunities.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global LKS treatment market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five). Read the full report: https://www.reportlinker.com/p06267903/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See original here:
Global LKS Treatment Market, By Type, By Treatment, By Diagnosis, By End User, By Region, Competition Forecast and Opportunities, 2017-2027 - Yahoo...

Hataali wins US patent for the use of blockchain in advanced medicinal therapy products – Bio-IT World

ATMPS Ltd/Hataali the leader in blockchain-based data sharing platforms for advanced therapies announces it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of blockchain technologies in personalised medicines. The company also has applications pending in both Europe and Asia as it looks to cement its technological advantage in the rapidly growing advanced therapy space globally.

The new patent comes at a key time for the pharma industry with more than ten advanced therapies anticipated to be approved in the next year as pharma companies continue to struggle with how to effectively and safely scale-up production. The challenge is that without a blockchain based solution like Hataali, they dont have a suitable platform to communicate and coordinate their activities to ensure effective commercialisation. Hataalis incorruptible data solution to track therapies through a complex supply chain ensures patient safety as well as more efficient regulatory compliance meaning a full digital solution with many in active trials still relying upon unsuitable paper-based tracking.

Its a big moment for Hataali as it means we have the exclusive use of blockchain the only technology so far proven to overcome the challenges of effective scale-up in advanced therapy medicinal products in the United States. Up until now, you have several companies trying to shoehorn in unsuitable old point to point technologies as a solution for cell and gene therapy tracking. They have simply not worked and we expect to take a dominant position over the next few years as it becomes apparent we have the only solution for a cost effective mass roll out of these therapies, commented Raja Sharif, CEO at Hataali.

The patent is also seen as a much wider pivotal moment for pharma as it accelerates adoption of blockchain technologies, which are already reaching wider maturity in the other industries like Fintech. Beyond solving the significant problem of cell and gene therapy tracking, blockchain will also empower the industry with potentially more streamlined applications and even payments whereby smart contracts offer the ability for providers to automate payments once clinical outcomes have been reached.

Sharif added: Hataali, being a single portal for multiple therapies, from multiple pharma companies for multiple sites will revolutionise the administration of cell and gene therapies. Our patent is one huge step along in helping the industry relieve the well documented congestion in therapy rollout and scale-up, as more pharma companies win approvals. The single portal approach makes it far easier for clinics to order and schedule these treatments. Without a robust technology to track products from vein to vein, we simply wont be able to get these lifesaving therapies out to the patients that need them quickly enough. Hataali solves this problem and will be a big enabler of the mass adoption of these next generation therapies.

ATMPS Ltd was also bestowed the Bionow Technical Service Award at the 20th Bionow Annual Awards Dinner in Manchester last week. The award recognised the Hataali blockchain-based platform for ATMP supply chains for its ability to allow its partners in personalised medicine to ensure that data necessary for the production of treatments can be shared between parties in a secure, confidential and regulatory compliant manner.

Read the original:
Hataali wins US patent for the use of blockchain in advanced medicinal therapy products - Bio-IT World

Five things for pharma marketers to know: Thursday, April 14, 2022 – Medical Marketing and Media

Uninsured Americans may have to pay for COVID-19 testing at certain labs due to federal funding running dry. The Senates $10 billion bipartisan pandemic aid bill doesnt include the Biden administrations request for $1.5 billion to cover testing and treatment for people without health insurance. (CNBC Weekly)

Bluebird Bios gene therapy Zynteglo, which has a proposed price of $2.1 million per treatment course, could still be cost-effective, according to the Institute for Clinical and Economic Review. The therapy is set to be reviewed by the Food and Drug Administration in June. (Endpoints News)

The U.S. Department of Justice is investigating Bausch Health over the marketing of skin condition medications. The inquiry is seeking information about the promotion of plaque psoriasis drugs Bryhali, Siliq and Duobrii for uses not approved by regulators. (STAT)

Halozyme Therapeutics announced that it will buy Antares Pharma for nearly $1 billion. The acquisition will allow Halozyme to expand into drug delivery and specialty medicines. (The Wall Street Journal)

STD cases soared during the pandemic, with gonorrhea and syphilis cases reaching record highs during the first year of COVID-19, according to new data from the Centers for Disease Control and Prevention). Despite high case counts, however, fewer federal funds are being directed to sexual health clinics. (Politico)

View post:
Five things for pharma marketers to know: Thursday, April 14, 2022 - Medical Marketing and Media

Beware of trans affirmation therapy | Julie Bindel – The Critic

Beware of trans affirmation therapy is the latest article in Julie Bindels online column for The Critic, The feminist fix, which explores feminisms answer to todays challenges. The previous article, on Will Smiths sexist excuses for violence, can be read here.

This week the government has banned conversion therapy for gays but, in a major kerfuffle, not for trans people. I wasnt surprised. As the EHRC rightly points out, the Government consultation document on the topic contained no clear definition of what will amount to conversion therapy. Neither was it clear about the meaning of transgender; a term which has no clear legal meaning, is potentially wider than the concept of gender reassignment in current UK law, and is understood by different people in different ways. So why all the confusion? What does this all mean for gay and dysphoric youth? And how does it relate to my own experience of conversion therapy?

In 2014, during research for a book on lesbian and gay culture I decided to challenge some of the mythology around what conversion therapy actually is and is not. I was sick of some conservative-minded gay men who would only speak out against conversion therapy because they believed that there is something such as a gay gene, and therefore sexuality is hard-wired in the womb. Their argument was, in a nutshell, that lesbians and gay men should be afforded tolerance on the basis that we cant help it.

These gay men argued that the born this way strategy would overcome prejudice and achieve equality. I disagree. Firstly, I have long been sceptical of the notion that sexual orientation is in any way predetermined. Even if the gay gene were found once and for all, what difference would it make?

Whether you are black, disabled, Jewish or belong to many oppressed minority groups may be determined at least in part by genes, but this has not prevented prejudice and discrimination towards these groups. To my mind, it is politically immature to argue for our rights on the grounds that we have no control over what and who we are.

I voluntarily undertook a gruelling week of intensive therapy

Although many lesbians experience our sexual desires as hard-wired from an early age, many others are only able to come out later in life having been railroaded into what feminists refer to as compulsory heterosexuality. This may include a variety of societal expectations, marriage to men, social opprobrium directed at lesbians and lesbian relationships, religion, and distaste for the depiction of lesbian relationships as they are portrayed in culture (e.g., porn). Many more women would be lesbians, these feminists argue, if they were freer from these constraints of patriarchy.

We are all subject to those forces, to different degrees and in different ways. Many lesbians and gay men have undergone more extreme and traumatic pressure, including conversion therapy. This therapy seeks to convert them to exclusively heterosexual practices (if not desires) and may involve extreme and abusive techniques.

Whilst researching my book, I went undercover, posing as a lesbian who wanted to be straight, in order to experience a gruelling week of intensive therapy. I was told, for eight hours each day, that I was broken, badly raised, sexually abused in childhood, mentally unwell, running from God. Even though I was in role, like an actor on set, I would return to my hotel every evening experiencing low moods, panic attacks and self-doubt.

I had been out as a lesbian for almost 40 years when I underwent this conversion therapy, and I was by no means forced or even persuaded to undergo it, but I still didnt escape the horrors, or the aftereffects. The effects of this type of therapy on a young person are often utterly devastating.

Trans Rights Activists in this debate are trying to compare the type of therapy I underwent to offering exploratory talking therapies to nonconforming or gender dysphoric young people. The only therapeutic approach acceptable to these extremists is the affirmation model. What does this look like for nonconforming and dysphoric youth?

As a 15-year-old I felt really grim about being a girl and a lesbian. Because I was attracted to girls, and rejected feminine frippery, I was constantly asked if I was a boy. Young women throughout the ages have had similar experiences, but nowadays if they go to a gender clinic, they may end up in affirmation therapy. They will be prescribed puberty blockers, followed by testosterone, double mastectomy, hysterectomy and lifelong medical treatment.

Rather than asking are you okay, this new model affirms teenagers in their chosen gender identities. Rather than asking whether teenagers are unhappy because they are being bullied for their sexuality, they are given unnecessary hormones. If they dont get these fast enough from one therapist, there is evidence that they go shopping for another one.

Growing up, girls are shamed for their periods; they watch their male peers overtake them in size and strength; they become subject to the male gaze; they are catcalled, objectified, sexually abused; they often feel powerless and sometimes out of control. For many of these girls, a male identification is a shield against all of this, maybe the first time theyve made a stand and tried to take up some space.

Being gay requires no hormones, surgeries or deception

Responsible, empathic therapy has to deal with this, and help these young women to understand why they feel how they do, before setting them on the road to a lifetime of unnecessary medical treatments. It is precisely this type of therapy that trans activists wish to ban.

They want to ban the type of support that would have helped me: a confused, self-hating teenager, who would have grabbed the opportunity to transition with both hands. And yet, here I am, an out and proud lesbian of more than 40 years.

That said, I really couldve done with some therapy when I was struggling with the feelings I had developed for a girl in my class a friendly, skilled ear, to listen to my distress and tell me I was perfectly fine as I was. A good dose of feminism would have helped me to understand why anti-lesbian prejudice exists, and how it contributed to my distress. The kids today are no different. But instead of being given the tools to fight their oppression, they are presenting at gender clinics and being put on hormones.

It is known that the majority of children who develop gender dysphoria go on to be lesbian or gay later in life, and continue to live as their biological sex, if only they can avoid being affirmed as trans and going down the medical pathway.

Being gay requires no hormones or surgeries, and no deception. On the other hand, instant affirmation of a trans identity for young gender nonconforming people is nothing more and nothing less than selling the medicalised lie to lesbian and gay young people: that they can somehow become straight. Affirmation therapy on the one hand, and gay conversion therapy on the other, are human rights violations and unacceptable on every level.

The feminist fix? Rather than telling confused children that the reason for their distress is that they are actually the opposite sex, give them a listening ear, and a good understanding of how women and girls are treated, and a feminist community, and some really good books. Turns out that the feminist fix is feminism.

Julie Bindels latest book,Feminism for Women: The Real Route to Liberation, was published in September 2021.

More:
Beware of trans affirmation therapy | Julie Bindel - The Critic

Sailing the Genome in Search of Safe Harbors – Technology Networks

Cell and gene therapies are poised to have a major impact on the landscape of modern medicine, carrying the potential to treat an array of different diseases with unmet clinical need.

However, the number of approved, clinically adopted cell and gene therapies is mere compared to the amount that are currently in development. A major barrier for the translation of such therapies is the safe integration of therapeutic genes into the human genome. The insertion of therapeutic genes bears the risk of off target effects, or integration of the gene into an unintended location.

A number of different strategies have been proposed to mitigate this effect. The most recent body of work comes from a collaboration between Harvards Wyss Institute for Biologically Inspired Engineering, Harvard Medical School (HMS) and the ETH Zurich in Switzerland.

Published in Cell Report Methods, the research focused on identifying safe spots in the genome. These locations, known as genomic safe harbors (GSHs), are areas in the genome that meet the following criteria: they can be accessed easily by genome-editing strategies, are within a safe distance from genes that possess functional properties and permit expression of a therapeutic gene, only once it has landed in the harbor. A simple analogy is deciding which harbor to dock a boat there are many considerations, and these depend on the type of boat you are sailing, the weather conditions and ease of access.

The research team adopted computational strategies that enabled the identification of 2,000 predicted GSHs. From this initial identification, they successfully validated two of the sites both in vitro and in vivo using reporter proteins.

Technology Networks interviewed the studys first author, Dr. Erik Aznauryan, research fellow in the laboratory of Professor George Church at Harvard Medical School. Aznauryan dives into further detail on the history of GSH research, the methods adopted to validate the GSH sites and the potential applications of this research.

Molly Campbell (MC): Can you talk about the history of genomic safe harbor research, and how they were discovered?

Erik Aznauryan (EA): Three genomic sites were empirically identified in previous studies to support stable expression of genes of interest in human cells: AAVS1, CCR5 and hRosa26. All these examples were established without any a-priori safety assessment of the genomic loci they reside in.

Attempts have been made to identify human GSH sites that would satisfy various safety criteria, thus avoiding the disadvantages of existing sites. One approach developed by Sadelain and colleagues used lentiviral transduction of beta-globin and green fluorescence protein genes into induced pluripotent stem cells (iPSCs), followed by the assessment of the integration sites in terms of their linear distance from various coding and regulatory elements in the genome, such as cancer genes, miRNAs and ultraconserved regions.

They discovered one lentiviral integration site that satisfied all of the proposed criteria, demonstrating sustainable expression upon erythroid differentiation of iPSCs. However, global transcriptome profile alterations of cells with transgenes integrated into this site were not assessed. A similar approach by Weiss and colleagues used lentiviral integrations in Chinese hamster ovary (CHO) cells to identify sites supporting long-term protein expression for biotechnological applications (e.g., recombinant monoclonal antibody production). Although this study led to the evaluation of multiple sites for durable, high-level transgene expression in CHO cells, no extrapolation to human genomic sites was carried out.

Another study aimed at identifying GSHs through bioinformatic search of mCreI sites regions targeted by monomerized version of I-CreI homing endonuclease found and characterized in green algae as capable to make targeted staggered double-strand DNA breaks residing in loci that satisfy GSH criteria. Like previous work, several stably expressing sites were identified and proposed for synthetic biology applications in humans. However, local and global gene expression profiling following integration events in these sites have not been conducted.

All these potential GSH sites possess a shared limitation of being narrowed by lentiviral- or mCreI-based integration mechanisms. Additionally, safety assessments of some of these identified sites, as well as previously established AAVS1, CCR5 and Rosa26, were carried out by evaluating the differential gene expression of genes located solely in the vicinity of these integration sites, without observing global transcriptomic changes following integration.

A more comprehensive bioinformatic-guided and genome-wide search of GSH sites based on established criteria, followed by experimental assessment of transgene expression durability in various cell types and safety assessment using global transcriptome profiling would, thus, lead to the identification of a more reliable and clinically useful genomic region.

MC: If GSHs do not encode proteins, or RNAs with functions in gene expression, or other cellular processes what is their function in the genome?

EA: In addition to protein coding, functional RNA coding, regulatory and structural regions of the human genome, other less well understood and inactive DNA regions exist.

A large proportion of the human genome seems to have evolved in the presence of a variety of integrating viruses which, as they inserted their DNA into the eukaryotic genome over the course of million years, lead to an establishment of vast non-coding elements that we continue to carry to this day. Furthermore, partial duplications of functional human genes have resulted in the formation of inactive pseudogenes, which occupy space in the genome yet are not known to bear cellular functions.

Finally, functional roles of some non-coding portions of the human genome are not well understood yet. Our search of safe harbors was conducted using existing annotation of the human genome, and as more components of it are deciphered the identification of genomic regions safe for gene insertion will become more informed.

MC: Are you able to discuss why some regions of the genome were previously regarded as GSHs but are now recognized as non-GSHs?

EA: In the absence of other alternatives, AAVS1, CCR5 and hRosa26 sites were historically called GSHs, as they supported the expression of genes of interest in a variety of cell types and were suitable for use in a research setting.

Their caveats (mainly, location within introns of functional genes, closely surrounded by other known protein coding genes as well as oncogenes) however prevent them from being used for clinical applications. Therefore, in our paper we dont call them GSHs, and refer to our newly discovered sites as GSHs.

MC: You thoroughly scanned the genome to identify candidate loci for further study as potential GSHs. Can you discuss some of the technological methods you adopted here, and why?

EA: We used several publicly available databases to identify genomic coordinates of structural, regulatory and coding components of the human genome according to the GSH criteria we outlined in the beginning of our study (outside genes, oncogenes, lncRNAs etc.,). We used these coordinates and bioinformatic tools such as command lines bedtools to exclude these genomic elements as well as areas adjacent to them. This left us with genomic regions putative GSHs from which we could then experimentally validate by inserting reporter and therapeutic genes into them followed by transcriptomic analysis of GSH-integrated vs non-integrated cells.

MC: You narrowed down your search to test five, and then two GSHs. Can you expand on your choice of reporter gene when assessing two GSHs in cell lines?

EA: Oftentimes in research you go with what is available or what is of the most interest to the lab you are currently working in.

Our case was not an exception, and we initially (up until the T cell work) used the mRuby reporter gene as it was widely available and extensively utilized and validated in our lab at ETH Zurich back then.

When I moved to the Wyss Institute at Harvard, I began collaborating with Dr. Denitsa Milanova, who was interested in testing these sites in the context of skin gene therapy particularly the treatment of junctional epidermolysis bullosa caused by mutations in various anchor proteins connecting different layers of skin, among which is the LAMB3 gene. For this reason, we decided to express this gene in human dermal fibroblasts, together with green fluorescent protein to have a visualizable confirmation of expression. We hope we would be able to translate this study into clinics.

MC: Can you describe examples of how GSHs can be utilized in potential therapeutics?

EA: Current cell therapy approaches rely on random insertion of genes of interest into the human genome. This can be associated with potential side effects including cancerous transformation of therapeutic cells as well as eventual silencing of the inserted gene.

We hope that current cell therapies will eventually transition to therapeutic gene insertions precisely into our GSHs, which will alleviate both described concerns. Specific areas of implementation may involve safer engineering of T cells for cancer treatment: insertion of genes encoding receptors targeting tumor cells or cytokines capable of enhancing anti-tumor response.

Additionally, these sites can be used for the engineering of skin cells for therapeutic (as discussed earlier with the LAMB3 example) as well as anti-aging applications, such as expression of genes that result in youthful skin phenotype.

Finally, given the robustness of gene expression from our identified sites, they can be used for industry-scale bio-manufacturing: high-yield production of proteins of interest in human cell lines for subsequent extraction and therapeutic applications (e.g., production of clotting factors for patients with hemophilias).

MC: Are there any limitations to the research at this stage?

EA: A primary limitation to this study is the low frequency of genomic integration events using CRISPR-based knock-in tools. This means that cells in which the gene of interest successfully integrated into the GSH must be pulled out of the vastly larger population of cells without this integration.

These isolated cells would then be expanded to generate homogenous population of gene-bearing cells. Such pipeline is not ideal for a clinical setting and improvements in gene integration efficiencies are needed to help this technology easier translate into clinics.

Our lab is currently working on developing genome engineering tools which would eventually allow to integrate large genes into GSHs with high precision and efficiency.

MC: What impact might this study have on the cell and gene therapy development space?

EA: This study will hopefully lead to many researchers in the field testing our sites, validating them in other therapeutically relevant cell types and eventually using them in research as well as in clinics as more reliable, durable and safe alternatives to current viral based random gene insertion methods.

Additionally, since in our work we shared all putative GSHs identified by our computational pipeline, we hope researchers will attempt to test sites we havent validated yet by implementing the GSH evaluation pipeline that we outlined in the paper. This will lead to identification of more GSHs with perhaps even better properties for clinical translation or bio-manufacturing.

MC: What are your next steps in advancing this work?

We hope to one day translate our successful in vitro skin results and start using these GSHs in an in vivo context.

Additionally, we are looking forward to improving integration efficiencies into our GSHs, which would further support clinical transition of our sites.

Finally, we will evaluate the usability of our GSHs for large-scale production of therapeutically relevant proteins, thus ameliorating the pipeline of manufacturing of biologics.

Dr. Erik Aznauryan was speaking to Molly Campbell, Senior Science Writer for Technology Networks.

Read this article:
Sailing the Genome in Search of Safe Harbors - Technology Networks